Therapeutic cancer vaccines, an exciting development in cancer immunotherapy, share the goal of creating and amplifying tumor-specific T-cell responses, but significant obstacles still remain to their success. In this meeting pioneering industry and academics will outline the cancer vaccine therapy and immunotherapy with a focus on novel vaccine platforms and antigens, underscoring the renewed optimism that has risen during pandemic. The field of therapeutic cancer vaccines is fast evolving, and while the diverse platforms or targets are currently being evaluated, valorisation of this yet-to-be established innovations stays challenging.
Programme
12:15 Walk-in, registration and lunch
13:00 Word of welcome
13:10 Sjoerd van der Burg, Professor of Cancer Immunology & Therapy
13:40 Gerben Moolhuizen, CEO ISA Pharmaceuticals
14:05 Katka Franke, Principal Scientist Frame Therapeutics
14:30 Coffee and tea break
15:00 Carl Figdor, Professor of Immunology
15:25 Erik Manting, CEO Immunicum AB
15:50 Panel discussion including EQT Life Sciences (former LSP) and Oncode Bridge Fund.
16:15 Networking drinks
17:30 End
Practical information
Date: September 28, 2022
Time: 12:15 pm – 17:30 pm
Venue: Pakhuis de Zwijger, Piet Heinkade 179, Amsterdam
Registration
Registration is now open! Please register here.
Who can join Biotech Wednesday?
Biotech Wednesday is open to all interested organisations and free of charge (max. 3 delegates per organisation) HollandBIO members and academia have priority.
Please note
HollandBIO follows the guidelines provided by the Dutch government and the National Institute for Public Health and the Environment (RIVM).
Source: HollandBIO